---
layout: default
title: Zinc Chloride
parent: Model Prediction Only (L5)
nav_order: 896
evidence_level: L5
indication_count: 3
---

# Zinc Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **3** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using conclusion from the evidence pack directly (no skill applies — this is a template-driven report generation task).

# Zinc Chloride: From Unestablished Indication to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

> Zinc chloride currently has no approved original indication or market presence recorded in India, and no mechanism-of-action data is available.
> The TxGNN model predicts it may be effective for **Severe Nonproliferative Diabetic Retinopathy**,
> but this prediction is **not currently supported by any clinical trials or published literature**.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not established — no approved indication or license record available (drug not marketed in India) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 (model prediction only; no clinical trials or literature) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for zinc chloride is not available, and no original approved indication is recorded in this evidence pack. Zinc chloride is a zinc salt typically used as a source of elemental zinc — for example as a trace-element additive in parenteral nutrition, or as a topical astringent/antiseptic — rather than as a drug with a well-defined single therapeutic indication.

Zinc is known to play physiological roles in retinal metabolism and antioxidant defense (e.g., as a cofactor for zinc-dependent enzymes such as superoxide dismutase, and in retinal pigment epithelium function). This provides a plausible, but currently unverified, biological rationale for a link between zinc and diabetic retinal disease. However, since no clinical trials or literature specific to this indication are present in the evidence pack, this rationale remains purely mechanistic/theoretical and has not been clinically tested.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## India Market Information

Zinc chloride is currently **not marketed in India** — no product registrations or license records are available in this evidence pack (total registrations: 0).

## Safety Considerations

- **Drug Interactions**: A total of **76 documented drug-drug interactions** were identified. Notable **Moderate**-level interactions include Tetracycline, Minocycline, and Levofloxacin (likely related to chelation reducing antibiotic absorption/efficacy). A larger group of **Minor**-level interactions was found with corticosteroids (Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Prednisone, Prednisolone) and immunomodulating/immunosuppressive agents (Abatacept, Adalimumab, Alefacept, Anakinra, Azathioprine, Baricitinib, Basiliximab, Belatacept, antilymphocyte/antithymocyte immunoglobulins).

Detailed safety labeling (key warnings and contraindications) is not yet available for this drug — this is flagged as a **blocking data gap** (see Conclusion below).

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (severe nonproliferative diabetic retinopathy) has no supporting clinical trials or literature (Evidence Level L5), the drug has no market presence or approved indication in India, and a **blocking data gap** on safety labeling (warnings/contraindications) prevents even an initial safety screening (S1).

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): obtain and parse official product labeling for warnings/contraindications to enable S1 safety screening
- Resolve DG002 (High): obtain mechanism of action data from DrugBank to support mechanistic plausibility assessment
- Confirm original approved indication(s) and regulatory history for zinc chloride, if any exist in other jurisdictions
- Search for clinical trials/literature specific to zinc chloride and diabetic retinopathy to move beyond model-prediction-only status

**Note:** Within this same evidence pack, a lower-ranked candidate — **dry eye syndrome** (rank 3, score 99.18%) — already has 2 completed clinical trials involving a zinc-chloride-derived compound (zinc-hyaluronate) and may warrant a separate, better-supported evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

